Derrong Lin Irene, Hertig John B
Purdue University, West Lafayette, IN, USA.
Butler University, Indianapolis, IN, USA.
Hosp Pharm. 2022 Jun;57(3):323-328. doi: 10.1177/00185787211037545. Epub 2021 Aug 5.
The relentless surges of global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections that caused the Covid-19 disease had pressured researchers and regulators to develop effective treatments quickly. While studying these therapies amid the pandemic, threats to patient care were reported, including (1) maintaining adequate safeguards as clinical effectiveness and safety data evolves, (2) risks from online counterfeit medications, and (3) disruption of the global pharmaceutical supply chain. This article discusses these patient safety threats and suggests strategies that promote patient safety, foster medication intelligence, and mitigate drug shortages. As the world continues to develop safe and effective treatments for Covid-19, patient safety is paramount. In response to the World Health Organization (WHO) Global Safety Challenge: Medication Without Harm, leaders must establish effective approaches to improve medication safety during the pandemic. Successfully integrating these leadership strategies with current practices allows pharmacy leaders to implement robust systems to reduce errors, prevent harm, and advocate for patient safety.
导致新冠肺炎疫情的全球严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染持续激增,给研究人员和监管机构带来了迅速开发有效治疗方法的压力。在疫情期间研究这些疗法时,报告了对患者护理的威胁,包括(1)随着临床有效性和安全性数据的演变维持适当的保障措施,(2)在线假药带来的风险,以及(3)全球药品供应链的中断。本文讨论了这些患者安全威胁,并提出了促进患者安全、培养用药知识和缓解药品短缺的策略。随着世界继续为新冠肺炎开发安全有效的治疗方法,患者安全至关重要。为应对世界卫生组织(WHO)的全球安全挑战:无害用药,领导者必须建立有效的方法,以在疫情期间提高用药安全性。成功地将这些领导策略与当前实践相结合,使药房领导者能够实施强大的系统,以减少错误、预防伤害并倡导患者安全。